Tech Xplore

Novo Nordisk signs deal with OpenAI to develop new drugs

Danish pharmaceuticals group Novo Nordisk, maker of the popular Ozempic and Wegovy anti-obesity drugs, announced Tuesday a ...

Danish firm Novo Nordisk joins hands with OpenAI to develop new drugs

The Danish pharmaceutical titan Novo Nordisk has entered a landmark collaboration with OpenAI to revolutionise the way ...

AI diffusion models tailor drug molecules to custom-fit protein targets, speeding drug development and evaluation

University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery ...

How Helical Puts AI In Reach Of Drug Developers And Researchers

A Luxembourg-based start-up has raised $10 million to help the pharmaceutical sector exploit the power of AI to drive faster ...
The News International

OpenAI-Novo Nordisk collaboration signals new era in AI-driven drug development

Artificial intelligence is revolutionizing medical science through cutting-edge diagnosis and AI-powered tools. Now, AI is ...
Morningstar

GNTbm's self-developed anti-cancer new drug GNTbm-38 has obtained IND approval from the U.S. FDA for Phase I clinical trials

TAIPEI, March 5, 2026 /PRNewswire/ -- Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator ...
Regulatory Affairs Professionals Society

Høeg touts FDA efforts to speed rare disease drugs to market

The top drug regulator at the US Food and Drug Administration (FDA) said the agency is working to develop new pathways for ...
Hosted on MSN

Amgen buys cancer drug developer Dark Blue in $840 million deal

(Bloomberg) -- Amgen Inc. has acquired cancer drug developer Dark Blue Therapeutics Ltd. in a deal worth as much as $840 million, expanding its portfolio of oncology treatments. Based in the UK, ...